prIME Symposium on SCCHN and CRC - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

prIME Symposium on SCCHN and CRC

Applying New Evidence to Patient Care

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based in Latin America. This activity may contain information on products outside the approved indications where you practice.

View downloadable slides for updates about the latest advances and emerging strategies in the management of squamous cell carcinoma of the head and neck (SCCHN) and colorectal cancer (CRC), and how to translate new evidence into clinical practice.

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

May 8, 2018

Expiration Date

May 8, 2019

Immunotherapy

Cancer immunotherapy: Key principles, concepts, and clinical applications

Featured Expert: Cristina Bonorino, PhD

Head and Neck Cancer

Locally advanced squamous cell carcinoma of the head and neck (SCCHN): Individualized treatment approach

Featured Expert: Aline Lauda Freitas Chaves, MD, MBA, MSc

Optimal treatment of recurrent/metastatic SCCHN: Front-line therapy and beyond

Featured Expert: Raúl E. Giglio, MD

Head and neck cancer management in the coming years: What can we expect?

Featured Expert: Kevin Harrington, MBBS, PhD, FRCP, FRCR

prIME Points™

Featured Expert: Raúl E. Giglio, MD

Colorectal Cancer

Improving outcomes in mCRC: Impact of clinical and molecular markers

Featured Expert: Clara Montagut, MD, PhD

Metastatic CRC with unresectable liver-only metastases: Multidisciplinary treatment approach

Featured Expert: Andre Deeke Sasse, MD, PhD

Managing mCRC across the disease continuum: Front-line therapy and treatment beyond progression

Featured Expert: Guillermo Méndez, MD

Colorectal cancer in the coming years: What can we expect?

Featured Expert: Clara Montagut, MD, PhD

prIME Points™

Featured Expert: Andre Deeke Sasse, MD, PhD

This educational activity is specifically designed for medical oncologists, radiation oncologists, head and neck surgeons/otolaryngologists, and other healthcare professionals interested and/or involved in the treatment of patients with head & neck cancer and CRC.

After successful completion of this educational activity, participants should be able to:

  • Describe immunotherapeutic principles and the evolving role of immunotherapy for the management of cancer, including SCCHN and metastatic CRC (mCRC)
  • Apply multidisciplinary approaches for managing HPV+ and HPV-, locally advanced SCCHN
  • Identify optimal treatment sequence for patients with recurrent/metastatic SCCHN
  • Explain state-of-the-art management of mCRC, and role of biomarkers to guide personalized therapy
  • Select optimal front-line therapy for individual patients with mCRC, including those with liver-only metastases, and determine best treatment sequence after disease progression

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and Independent Medical Education (IME) performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Bonorino has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Chaves has disclosed that she received speaking and teaching fees from Bristol-Myers Squibb and Merck Serono. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Giglio has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Harrington has disclosed that he received board membership fees from AstraZeneca, Bristol-Myers Squibb, Merck, MSD, and Pfizer. He also received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and MSD. He has received honoraria for promotional speaker’s bureau Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and MSD. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mendez has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Montagut has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Sasse has disclosed receipt of fees for consulting and membership on an advisory committee or review panel and speaking and teaching fees from Merck and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD, MSc (medical director content reviewer/planner) – no relevant financial relationships
  • Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.